1

1	
2	Single cell sequencing analysis uncovers genetics-influenced CD16+monocytes and memory
3	CD8+T cells involved in severe COVID-19
4	Yunlong Ma ^{1,†} , Fei Qiu ^{1,†} , Chunyu Deng ^{1,†} , Jingjing Li ^{2,†} , Yukuan Huang ^{1,†} , Zeyi Wu ¹ , Yijun Zhou ¹ ,
5	Yaru Zhang ¹ , Yichun Xiong ³ , Yinghao Yao ³ , Yigang Zhong ⁴ , Jia Qu ¹ , Jianzhong Su ^{1,3*}
6	
7	¹ Institute of Biomedical Big Data, School of Ophthalmology & Optometry and Eye Hospital,
8	School of Biomedical Engineering, Wenzhou Medical University, Wenzhou, 325027, China.
9	² State Key Laboratory for Diagnosis and Treatment of Infectious Diseases, the First Affiliated
10	Hospital, Collaborative Innovation Center for Diagnosis and Treatment of Infectious Diseases,
11	Zhejiang University School of Medicine, Hangzhou 310003, Zhejiang, China.
12	³ Wenzhou Institute, University of Chinese Academy of Sciences, Wenzhou 325011, China.
13	⁴ Department of Cardiology, Affiliated Hangzhou First People's Hospital, Zhejiang University
14	school of Medicine, Hangzhou, China.
15	[†] These authors contributed equally to this work.
16	
17	*Correspondence should be addressed to:
18	Jianzhong Su: <u>sujz@wmu.edu.cn;</u>
19	¹ Institute of Biomedical Big Data, School of Ophthalmology & Optometry and Eye Hospital,
20	Wenzhou Medical University, Wenzhou, 325027, China.
21	³ Wenzhou Institute, University of Chinese Academy of Sciences, Wenzhou 325011, China.
22	
23	
24	
25	

26

Abstract

Background: Understanding the host genetic architecture and viral immunity contributes to the development of effective vaccines and therapeutics for controlling the COVID-19 pandemic. Alterations of immune responses in peripheral blood mononuclear cells play a crucial role in the detrimental progression of COVID-19. However, the effects of host genetic factors on immune responses for severe COVID-19 remain largely unknown.

Methods: We constructed a powerful computational framework to characterize the host geneticsinfluenced immune cell subpopulations for severe COVID-19 by integrating GWAS summary

statistics (N = 969,689 samples) with four independent scRNA-seq datasets (N = 606,534 cells).

Results: We found that 34 risk genes were significantly associated with severe COVID-19, and the 35 number of highly-expressed genetics-risk genes increased with the severity of COVID-19. Three 36 cell-subtypes that are CD16+monocytes, megakaryocytes, and memory CD8+T cells were 37 significantly enriched by COVID-19-related genetic association signals. Notably, three causal risk 38 genes of CCR1, CXCR6, and ABO were specifically expressed in these three cell types, respectively. 39 $CCR1^+$ CD16+monocytes and ABO^+ megakaryocytes with significant up-regulated genes including 40 S100A12, S100A8, S100A9, and IFITM1 confer higher risk to the cytokine storms among severe 41 42 patients. $CXCR6^+$ memory CD8+ T cells exhibit a notable polyfunctionality of multiple immunologic features, including elevation of proliferation, migration, and chemotaxis. Moreover, 43 we observed a prominent increase in cell-cell interactions of both CCR1⁺ CD16+monocytes and 44 45 $CXCR6^+$ memory CD8+T cells in severe patients compared to normal controls among both PBMCs and lung tissues, and elevated interactions with epithelial cells could contribute to enhance the 46 resident to lung airway for against COVID-19 infection. 47

48 **Conclusions**: We uncover a major genetics-modulated immunological shift between mild and 49 severe infection, including an increase in up-regulated genetic-risk genes, excessive secreted 50 inflammatory cytokines, and functional immune cell subsets contributing high risk to severity,

which provides novel insights in parsing the host genetics-influenced immune cells for severeCOVID-19.

53 **Keywords:** Single cell sequencing, GWAS, immune cells, inflammatory storm, COVID-19

- 54
- 55

Background

The coronavirus disease 2019 (COVID-19) outbreak, caused by severe acute respiratory 56 syndrome coronavirus 2 (SARS-CoV-2), has widely and severely jeopardized the health and 57 economy systems of most countries worldwide. As of July 21th, 2021, there were more than 192.2 58 million confirmed patients with more than 4.12 million deaths in the whole world [1]. COVID-19 59 has distinct clinical manifestations ranging from asymptomatic to severe respiratory failure [2]. 60 Mortalities of COVID-19 are largely derived from severe patients with interstitial pneumonia in 61 both lungs and acute respiratory distress syndrome [3]. Many earlier studies [4-6] have shown that 62 the number of severe COVID-19 patients who are elders and have comorbidities, such as diabetes 63 and hypertension, has increased. In this connection, understanding the immunologic mechanism of 64 severe COVID-19 and identifying novel vaccine targets to control the pandemic are of considerable 65 interest. 66

Accumulating evidence have suggested that alterations of immune responses in peripheral 67 blood mononuclear cells (PBMCs) and bronchoalveolar lavage fluid (BALF) play a crucial role in 68 the detrimental progression of COVID-19 [7, 8]. There has been evidence that cytokine storm, 69 usually found in severe COVID-19 patients, causes the adverse progression of COVID-19 [7]. 70 Increased circulating levels of proinflammatory cytokine, including IL-10, IL-6 and TNF- α , have 71 been reported to be associated with severe COVID-19 [7, 9]. Single-cell RNA sequencing (scRNA-72 seq) has been extensively utilized to reveal the immune responses of COVID-19 patients in both 73 74 lung and peripheral blood [10-18]. Megakaryocytes and monocytes [11, 12], T cells exhaustion [14], lymphopenia [19], and increased levels of cytokines [20] may cause aberrant peripheral 75

immune activities in severe COVID-19 patients. Based on large-scale samples, previous studies identified that dysregulation of mTOR signaling pathway in dendritic cells [21] and aberrant myeloid cell subpopulations [16, 17] implicated in severe COVID-19. Su et al. [10] revealed an increase in inflammation and a sharp drop in blood nutrients between mild and moderate-to-severe COVID-19, and new subsets of immune cells emerged in moderate COVID-19 patients.

81 Genome-wide association study (GWAS) has emerged as a powerful approach to identify risk genes and genetic variants for complex diseases. By gathering population-based GWAS data 82 worldwide, the COVID-19 Host Genetic Consortium has launched the "COVID-19 Host Genetics 83 84 Initiative" project to facilitate COVID-19 host genetic research and identify genetic determinants of COVID-19 [22]. Subsequently, a growing number of GWASs have identified numerous 85 significant genetic variants associated with COVID-19 susceptibility and severity [23-28]. 86 87 Ellinghaus et al. [27] performed a meta-analysis of two independent GWAS datasets with 1,610 severe COVID-19 patients and 2,205 matched controls at seven hospitals in the Italian and Spanish 88 epicenters, and identified two susceptibility loci of 3p21.31 and 9q34.2 to be significantly 89 associated with severe COVID-19 at the genome-wide level. Based on a large-scale meta-analysis 90 (N = 680, 128), our group found that the *IFNAR2-IL10RB* gene cluster were significantly associated 91 92 with COVID-19 susceptibility, and suggested that *IFNAR2* and *IL10RB* might have regulatory roles 93 in the pulmonary immune response based on scRNA-seq data [25]. Consistently, Pairo-Gastineira 94 et al. [24] conducted a GWAS study based on 2,244 critically ill COVID-19 patients and highlighted 95 that several genes including IFNAR2, DPP9, and OAS1 were significantly associated with severe COVID-19 at a genome-wide significance. 96

Two primary hypotheses were proposed for the involvement of immune genes in severe COVID-19 susceptibility. Whether the severe COVID-19-related risk genes associated with defective innate immune responses would induce persistent viral replication and resultant high viral loads, and whether an exaggerated genetically-mediated cytokine production contributes to the

hyper-inflammation and poor outcome among severe COVID-19. However, the effects of these
genetic determinants on the peripheral immune cells for severe COVID-19 remain largely unknown.
In view of a purely genetic study or single cell sequencing study cannot address this critical question,
we here leveraged comprehensive computational methods to combine a large-scale GWAS
summary dataset with scRNA-seq data for identifying host genetics-influenced immune cell
subpopulations involved in the etiology of severe COVID-19.

- 107
- 108

Methods

109 Single cell RNA-seq data on severe COVID-19

In this study, we downloaded four independent scRNA-seq datasets on COVID-19 in PBMC 110 and BALF from the ArrayExpress database (Dataset #1, the accession number is E-MTAB-9357 111 from Su et al. study [10]), and the Gene Expression Omnibus (GEO) database (Dataset #2, the 112 accession number is GSE149689 from Lee et al. study [18], Dataset #3, the accession number is 113 GSE150861 from Guo et al. study [11], and Dataset #4, the accession number is GSE158055 [29]). 114 The first dataset contained 270 peripheral blood samples including 254 samples with different 115 COVID-19 severity (i.e., mild N = 109, moderate N = 102, and severe N = 50) and 16 healthy 116 117 controls for scRNA-seq analysis. There were eight patients in dataset #2 with COVID-19 of varying clinical severity, including asymptomatic, mild, and severe, and four healthy controls with PBMCs. 118 The dataset #3 included five peripheral blood samples collected from two severe COVID-19 119 patients at three different time points during tocilizumab treatment, containing two different stages: 120 severe stage and remission stage. Within the dataset #4, 12 BALF samples were collected from 121 lung tissues, including three moderate and nine severe patients. For all the datasets, the sample 122 collection process were reviewed and approved by Institutional Review Board at the institutions 123 124 where samples were originally collected. The COVID-19 severity was evaluated by using the World Health Organization (WHO) ordinal scale (WOS), the National Early Warning Score (NEWS), or 125

- the Diagnosis and Treatment of COVID-19 (Trail Version 6). Single-cell transcriptomes for these
- 127 four datasets were gathered using the $10 \times$ Genomics scRNA-seq platform.
- 128

129 Single cell RNA sequencing data processing

We performed normalization, clustering, and dimensionality reduction, differential expression 130 gene (DEG) analysis, and visualization on these four independent scRNA-seq datasets with the 131 Seurat R package [30]. The SCTransform function was used to scale and transform data, and linear 132 regression model was applied to omit redundant variations caused by cellular complexity (i.e., cells 133 expressed less than 200 genes or more than 2,500 genes were removed) or cellular quality (i.e., 134 cells that had UMIs more than 10,000 and expressed reads of mitochondrial genes greater than 10% 135 were removed). The *CellCycleSoring* function was applied to remove the effects of confounding 136 factors. Principal component analysis (PCA) was carried out to extract principal components (PCs) 137 that could explain most of datasets via using high variable genes. Top 20 PCs were utilized to 138 conduct uniform manifold approximation and projection (UMAP) to embed the dataset into two 139 dimensions. Subsequently, we constructed a shared nearest-neighbor graph (SNN) using the 140 FindNeighbors function based on the top 20 PCs, and applied a graph-based modularity-141 optimization algorithm from the Louvain method [31] on this SNN for clustering the dataset with 142 the cluster resolution set to 0.5. We used the RunHarmony function with PCA reduction method 143 from harmony R package [32] to integrate samples to correct batch effects. The 144 145 FindConservedMarkers function in Seurat was implemented to find differential expressed genes for determining cellular identity. Well-defined markers were used to annotate clusters, and 146 uncharacterized clusters in the first round of clustering were extracted to run the second round of 147 clustering (Supplemental Table S2). A total of 606,534 cells with 563,856 PBMC cells and 42,678 148 149 BALF cells were yielded from 300 samples based on the four independent scRNA-seq datasets (Supplemental Table S1 and Figure 1A). To allow comparison across samples and datasets, we 150

used a common dictionary of gene symbols to annotate genes and these unrecognized symbols were

152 removed.

153

154 GWAS summary data on hospitalized COVID-19

The meta-GWAS summary data on severe COVID-19 round 4 (B2 ALL, Susceptibility 155 [Hospitalized COVID-19 vs. Population]) were downloaded from the official website of the 156 COVID-19 Host Genetic Consortium [22] (https://www.covid19hg.org/; analyzed file named: 157 "COVID19 HGI B2 ALL leave 23andme 20201020.txt.gz"; released date of October 4 2020). 158 There were 7.885 hospitalized COVID-19 patients and 961,804 control participants from 21 159 independent contributing studies. There was an overwhelming majority of participants in these 160 contributing studies with European ancestry (93%). The meta-GWAS summary statistics contained 161 P values, Wald statistic, inverse-variance meta-analyzed log Odds Ratio (OR) and related standard 162 errors. The 1,000 Genomes Project European Phase 3 [33] was used as a panel for pruning. Results 163 from 23&Me cohort GWAS summary statistics were excluded from our current analysis. Genetic 164 variants without RefSNP number in the Human Genome reference builds 37 were filtered out, 165 giving a total of 9,368,170 genetic variants satisfying the major allele frequency (MAF) over 0.0001 166 and the imputation score of greater tha 0.6. We used the *qqman* R package to figure both Manhattan 167 and quantile-quantile (QQ) plot, and the web-based software of LocusZoom 168 plot (http://locuszoom.sph.umich.edu/)[34] to visualize the regional association plots for significant risk 169 loci. 170

171

172 Hierarchical clustering analysis

To examine the similarity of the transcriptome profiles between cell types across different COVID-19 severities (Supplemental Figure S4), we merged the counts of UMI for each cell type according to normal, mild, moderate, and severe COVID-19. In order to normalize gene expression,

we divided the counts of UMI for each gene by the counts of total UMI for all genes in each cell type and then multiplied by 100,000, as refer to the method in a previous study [18]. A median expression value of greater than 0.5 was used to calculate the relative change in each gene expression by dividing it by the median value for each gene, and the Pearson correlation coefficient (PPC) of the relative change in gene expression was used for current hierarchical clustering analysis.

181

182 Gene-based association analysis

To perform a gene-based genetic association analysis of the meta-GWAS summary statistics on severe COVID-19, we leveraged the updated SNP-wise Mean model of MAGMA [35]. In this model, MAGMA computes a test statistic:

$$T = \sum_{i}^{N} Z_{i}^{2} = \mathbf{Z}^{T} \mathbf{Z}$$

where N is the number of SNPs mapped in a gene and $Z_i = \phi(p_i)$. Of note, ϕ is the cumulative 187 normal distribution function and p_i is the marginal P value for a given SNP *i*. SNPs belonging to 188 a specific gene were based on whether located in the gene body or within the +/- 20 kb upstream or 189 downstream region of the gene. Furthermore, the model assumes $Z \sim MVN(\theta, S)$, where S is the 190 191 LD matrix of the SNP genotypes. The LD matrix can be diagonalized and hence written as $S = QAQ^T$, where Q is an orthogonal matrix and $A = \text{diag}(\lambda_1, \lambda_2, ..., \lambda_N)$ with λ_j being the *j*th 192 193 eigenvalue of S. The 1,000 Genomes Project Phase 3 European Panel [33] was used for calculating the LD information among SNPs extracted from GWAS summary data on COVID-19. 194 $D \sim \text{MVN}(\theta, I_{\kappa})$ is a random variable, where $D = A^{-0.5}Q^T Z$. Then the sum of squared SNP Z-195 196 statistics as the following formula:

197
$$T = \mathbf{Z}^T \mathbf{Z} = (\mathbf{Q} \mathbf{A}^{0.5} \mathbf{D})^T \mathbf{Q} \mathbf{A}^{0.5} \mathbf{D} = \mathbf{D}^T \mathbf{A} \mathbf{D} = \sum_i^N \lambda_i D_i^2$$

with $D_i \sim N(0,1)$ and $D_i^2 \sim \chi_1^2$. Namely, *T* follows a mixture distribution of independent χ_1^2 random variables. A total of 19,138 genes were included in the current analysis. We used the Benjamini-Hochberg false discovery rate (FDR) method, in which a gene with a FDR ≤ 0.05 (P \leq 6.8×10^{-5}) was interpreted as significant, to adjust for multiple testing.

202

203 Pathway enrichment analysis

We applied the *built-in* functions of MAGMA [35], using the results from GWAS summary 204 statistics as its input, to examine genome-wide enriched biological pathways for severe COVID-19. 205 We calculated competitive P values by examining the results that the combined effect of genes 206 within a pathway is significantly greater than the combined effect of all other genes, and 10,000 207 permutations was used to adjust competitive P values. Additionally, we leveraged the over-208 representation algorithm of the WebGestalt (http://www.webgestalt.org) [36] along with the 209 significant genes as an input list to conduct a pathway enrichment analysis using the KEGG 210 pathway resource [37]. The number of genes in each pathway was set to between 5 and 2,000, and 211 the Benjamini-Hochberg FDR was used for multiple correction. To cluster these identified KEGG 212 213 pathways, we performed a multidimensional scaling (MDS) analysis based on the Jaccard distance method [38], and constructed a pathway-pathway interaction network for these significantly 214 enriched pathways setting the Jaccard distance > 0.1. 215

216

217 Combining GWAS-based genetic signals with eQTL data

To uncover genetically-regulatory expression of genes associated with severe COVID-19, we conducted an integrative genomics analysis by using the S-PrediXcan [39] by combining meta-GWAS summary statistics with expression quantitative trait loci (eQTL) data for 49 tissues from the GTEx Project (version 8). S-PrediXcan mainly uses two linear regression models to analyze the association between predicted gene expression and severe COVID-19:

223
$$Y = \alpha_1 + X_1 \beta_1 + \varepsilon_1$$

224
$$\boldsymbol{Y} = \boldsymbol{\alpha}_2 + \boldsymbol{G}_g \boldsymbol{\gamma}_g + \boldsymbol{\varepsilon}_2$$

where $\boldsymbol{\alpha}_1$ and $\boldsymbol{\alpha}_2$ are intercepts, $\boldsymbol{\varepsilon}_1$ and $\boldsymbol{\varepsilon}_2$ are independent error terms, \boldsymbol{Y} is the *n* dimensional vector for *n* individuals, \boldsymbol{X}_l is the allelic dosage for SNP *l* in n individuals, $\boldsymbol{\beta}_l$ is the effect size of SNP *l*, $\boldsymbol{G}_g = \sum_{i \in gene(g)} \omega_{ig} \boldsymbol{X}_i$ is the predicted expression calculated by ω_{lg} and \boldsymbol{X}_l , in which ω_{lg} is derived from the GTEx Project, and γ_g is the effect size of \boldsymbol{G}_g . The Z-score (Wald-statistic) of the association between predicted gene expression and severe COVID-19 can be transformed as:

230
$$Z_{g} = \frac{\hat{\gamma}_{g}}{\operatorname{se}(\hat{\gamma}_{g})} \approx \sum_{i \in gene(g)} \omega_{ig} \frac{\hat{\sigma}_{i}}{\hat{\sigma}_{g}} \frac{\hat{\beta}_{i}}{\operatorname{se}(\hat{\beta}_{i})}$$

where $\hat{\sigma}_{g}$ is the standard deviation of \boldsymbol{G}_{g} and can be calculated from the 1,000 Genomes Project European Phase 3 Panel, $\hat{\beta}_{l}$ is the effect size from GWAS on COVID-19 and $\hat{\sigma}_{l}$ is the standard deviation of $\hat{\beta}_{l}$. S-PrediXcan was run for each of 49 tissues with 659,158 gene-tissue pairs.

Furthermore, to increase the power to discover significant genes whose expression has similar regulations across multi-tissues, we utilized the S-MultiXcan [40] to meta-analyze these results from above S-PrediXcan analysis. S-MultiXcan fits a linear regression model of severe COVID-19 on predicted expression from multiple tissue models jointly:

238
$$\boldsymbol{Y} = \sum_{j=1}^{p} \boldsymbol{T}_{j} \boldsymbol{g}_{j} + \boldsymbol{e} = \boldsymbol{T} \boldsymbol{g} + \boldsymbol{e}$$

where $\tilde{T}_{j} = \sum_{i \in gene(j)} \omega_{i} X_{i}$ is the predicted expression of tissue j, and T_{j} is the standardization of \tilde{T}_{j} to *mean* = 0 and *standard deviation* = 1. g_{j} is the effect size for the predicted gene expression in tissue j, e is an error term with variance σ_{e}^{2} , and p is the number of included tissues. There were 22,326 genes across 49 GTEx tissues with integrated convergent evidence in S-MultiXcan, and a gene with a value of FDR ≤ 0.05 (P $\leq 3.8 \times 10^{-5}$) is considered to be significant.

244

245 In silico permutation analysis

To explore the concordance of results from both MAGMA analysis (Gene set #1: N = 944, P246 ≤ 0.05) and S-MultiXcan analysis (Gene set #2: N =1,274, P ≤ 0.05), we performed an *in silico* 247 permutation analysis which consisted 100,000 times (N_{Total}) random selections [41, 42]. We first 248 calculated the number of overlapped genes between Gene Set #1 and #2 ($N_{\text{Observation}} = 302$), then 249 employed the total number of genes in S-MultiXcan analysis as background genes ($N_{\text{Background}} =$ 250 22,326). By randomly selecting the same number of genes as Gene set #2 (N = 1,274) from the 251 background genes, and after repeating it 100,000 times, we calculated the number of overlapped 252 genes between Gene Set #1 and the sample we selected each time (N_{Random}). Finally, we calculated 253 the empirically permuted P value using the following formula: $P = \frac{N_{Random} \ge N_{Observation}}{N_{Total}}$, and 254 empirical P value ≤ 0.05 is considered to be significant. 255

256

257 Drug-gene interaction analysis

We conducted a drug-gene interaction analysis for identified genetics-risk genes by using 258 protein-chemical interactions in the context of STRING-based PPI networks [43] and STITCH-259 based drug annotation information (v5.0, http://stitch.embl.de/) [44]. Only experimentally-260 validated gene-drug interactions with ranked confidence score were selected for constructing a 261 drug-gene interaction network. To examine the potential therapeutic effects of highly-expressed 262 genes in each immune cell, we conducted an enrichment analysis of 43 druggable categories based 263 on the DGIdb database (https://www.dgidb.org/druggable gene categories). Additionally, we 264 265 collected 1,263 human druggable proteins, which are therapeutic targets of clinical stage or approved drugs, from a previous study [26]. Among them, 704 proteins are targets for potential 266 COVID-19-relevant drugs based on registers of clinical trials for COVID-19, approved 267

- 268 immunomodulatory/anticoagulant drugs, or have biological functions associated with SARS-CoV-
- 269 2 infection (Supplemental Table S11).
- 270

271 Integrated analysis of GWAS summary statistics and scRNA-seq data

To identify genetically regulatory-related peripheral immune cells for severe COVID-19, we implemented the RolyPoly algorithm [45] to incorporate GWAS summary statistics with scRNAseq data. Let g(i) stands for the gene associated with SNP i, $S_j = \{i : g(i) = j\}$ be the SNP set with multiple SNPs associated with the gene j, and β_{s_j} be a GWAS-based effect-size vector of S_j with a *priori* assumption that $\beta_{s_j} \sim MVN(0, \sigma_j^2 I_{s_j})$. Following the *priori*, RolyPoly gives a polygenic

2// Intear model for
$$\boldsymbol{p}_{s_j}$$
:

278
$$\sigma_j^2 = \gamma_0 + \sum_{i=1}^N \gamma_i \alpha_{ji}$$

where γ_0 is an intercept term, α_{ji} (*i* = 1,2,...,*N*) are annotations such as cell-type-specific gene expression, and γ_i are annotation coefficients for α_{ji} . To fit the observed and expected sum squared SNP effect sizes related to each gene by using the method-of-moments estimators, RolyPoly estimates γ_i by the following equation:

283
$$E(\sum_{i\in S_j} \hat{\beta}_i^2) = \sigma_j^2 \operatorname{Tr}(\boldsymbol{R}_{S_j}^2) + |S_j| \sigma_e^2 n^{-1}$$

where R_{s_j} is the LD matrix of S_j and Tr represents the trace of a matrix. Finally, RolyPoly applies the block bootstrap method with 1,000 iterations to estimate standard errors $\hat{\sigma}_{\gamma_i}$ for calculating a *t*statistic and corresponding P values. The PLINK (v1.90) [46] was used to calculate the LD between SNPs within the 1 Mb window based on the 1,000 Genome Project European Phase 3 panel [33]. We restricted the analysis to SNPs in the autosomes, and any SNPs with MAF \leq 5% were excluded.

The major histocompatibility complex region (Chr6: 25-35 Mbp) was also excluded due to the extensive LD in this region.

291

292 Defining cell state scores

We leveraged cell state scores to assess the immunological degree of each immune cell type 293 expressed a pre-curated expression gene set [11, 14, 29]. The cell state scores (CTS) were calculated 294 based on the average expression of genes from the pre-curated gene set in the respective cell with 295 the following formula: CTSk(m) = average(RE(GSk, m)) - average(RE(GSn, m))), where GSk is a 296 297 pre-defined gene set k in a given cell m, and GSn is a control gene set that was randomly chosen on the basis of aggregate expression levels bins, which obtain a comparable distribution of expression 298 levels and over size to that of the pre-curated gene set. RE represents the relative expression of GSk 299 or GSn. The AddModuleScore function in Seurat [30] was applied to calculate the CTS with default 300 parameters. We used the inflammatory and cytokine genes (N = 324 genes, Supplemental Table 301 S10), cytokine-cytokine receptor interactions (N = 294 genes), chemokine signaling pathway (N =302 189 genes), T cell activation (GO: 0042110), response to interferon alpha (GO: 0035455), response 303 to interferon beta (GO: 0035456), leukocyte migration (GO: 0050900), 5 well-defined proliferating 304 305 markers (MK167, TYMS, NKG7, IL7R, and CCR7), 6 well-defined exhaustion markers (LAG3, TIGIT, PDCD1, CTLA4, HAVCR2, and TOX), and 12 cytotoxicity-associated genes (PRF1, IFNG, 306 GNLY, NKG7, GZMB, GZMA, GZMH, KLRK1, KLRB1, KLRD1, CTSW, and CST7) to define 307 308 inflammatory cytokine, chemokine, T cell activation, IFN- α/β response, migration, proliferation, exhaustion, and cytotoxicity score, respectively. 309

310

311 Cell-to-cell interaction analysis

To identify potential cellular interactions of $CCR1^+$ CD16+monocytes and $CXCR6^+$ memory CD8+T cells with other immune cells, we utilized the CellChat R package [47] for inferring the

predicted cell-to-cell communications based on two normalized scRNA-seq datasets (dataset #1 of PBMC and dataset #4 of BALF). CellChat algorithm could examine the significance of ligandreceptor interactions between two cell types depending on the expression of important factors, including stimulatory and inhibitory membrane-bound co-receptors, soluble agonists and antagonists. The communication probability of a signaling pathway was derived from the sum of probabilities of their ligand-receptor interactions. We only concentrated on the ligand-receptor interactions that significantly associated with severe COVID-19 compared with normal control.

321

322 Statistical analysis

The Wilcoxon sum-rank test was used to assess DEGs in mild, moderate, and severe COVID-323 19 group compared with normal control. The Mann-Kendall trend analysis was applied to evaluate 324 the significance of cell state cells with elevated severities of COVID-19. Pathway- and disease-325 based enrichment analyses used the hypergeometric test to identify remarkable biological pathways 326 and disease-terms. The Pearson correlation analysis was used to calculate the correlation coefficient 327 of highly-expressed genes in CCR1⁺ CD16+monocytes between moderate and severe patients. The 328 paired Student's t test was used to calculate the significance of ligand/receptor interactions of 329 CCR1⁺ CD16+monocytes and CXCR6⁺ memory CD8+T cells with other immune cells between 330 normal control and severe COVID-19. 331

- 332
- 333

Results

334 The computational framework for integrating single-cell transcriptomes and GWAS on COVID-

335 **19**

As shown in Figure 1, we devised a computational framework to parse the host geneticsmodulated immune cell subpopulations implicated in severe COVID-19. It included three main parts: 1) integrative analysis that combined GWAS summary statistics with scRNA-seq data to

genetically map single-cell landscape for severe COVID-19 (Figure 1A); 2) identifying geneticsrisk genes, pathways, and immune cell subpopulations that contributed to cytokine storms among
severe patients (Figure 1B); and 3) uncovering the cellular interactions of genetics-modulated
immune cell subsets, as well as their functions with cells in lung tissues (Figure 1C).

343

344 Identification of immune cell types associated with severe COVID-19

To parse the host genetics-influenced immune responses at single cellular level in PBMCs for 345 severe COVID-19, we subjected three independent scRNA-seq datasets with 563,856 cells to 346 UMAP based on highly variable genes using the Seurat (See Methods) [30]. There was 347 identification of 13 distinct clusters unbiased by patients with different severities (Supplemental 348 Figure S1). We leveraged well-known marker genes to assign these clusters to 13 distinct cell types, 349 including mature B cells, megakaryocytes, na ve B cells, CD34+progenitors, dendritic cells, natural 350 killer (NK) cells, CD14+monocytes, CD16+monocytes, memory CD4+T cells, na we CD4+T cells, 351 na we CD8+T cells, memory CD8+T cells, and effector CD8+T cells (Supplemental Figures S2-352 S3). 353

While performing the hierarchical clustering analysis on the scRNA-seq profiles, we 354 discovered that cell types were the primary determinants of their clustering, followed by disease 355 severities, indicating both COVID-19 pathology and immune cell types might have crucial roles in 356 altered patterns of immune transcriptome instead of technical artifacts (Supplemental Figure S4). 357 As a vital feature for reflecting the alterations of immune responses, we examined the relative 358 proportions of peripheral immune cells across different COVID-19 groups in comparison with 359 normal group. The proportions of CD14+monocytes, megakaryocytes, and CD34+progenitors were 360 significantly elevated in moderate and severe patients, whereas the proportions of 361 362 CD16+monocytes, effector CD8+ T cells, memory CD8+T cells, memory CD4+T cells, na we

363 CD4+T cells, and NK cells were significantly decreased with the increased severities 364 (Supplemental Figure S5).

365

366 Identification of genetic risk loci associated with severe COVID-19

Through performing a meta-analysis of 21 independent GWAS studies from the COVID-19 367 Host Genetic Consortium, eight genomic loci were identified to be associated with hospitalized 368 COVID-19 at a genome-wide significant level, including 1p22.2 (rs2166172, $P = 2.74 \times 10^{-8}$), 369 3p21.31 (rs35081325, P = 3.32×10^{-58} , and rs33998492, P = 3.59×10^{-14}), 6p21.33 (rs143334143, P 370 $= 1.28 \times 10^{-10}$, 7p11.2 (rs622568, P = 2.57 × 10⁻⁸), 9q34.2 (rs505922, P = 2.24 × 10⁻⁹), 12q24.13 371 $(rs2269899, P = 3.24 \times 10^{-8})$, 19p13.3 $(rs2109069, P = 6.4 \times 10^{-13})$, and 21q22.11 $(rs13050728, P = 6.4 \times 10^{-13})$ 372 $=1.91 \times 10^{-11}$) (Figure 2A, Supplemental Table S3, Figure S6, and Materials S2). Among these eight 373 loci, three loci, 1p22.2, 6p21.33 and 7p11.2, were newly identified. It should be noted that there 374 were two independent genetic association signals (Index SNPs: rs35081325 and rs33998492) in the 375 3p21.31 locus for severe COVID-19 (Figure 2B and Supplemental Figure S7A-C). Using the 376 Variant2Gene (V2G) algorithm [48], we prioritized CXCR6 as a candidate causal gene for 377 rs35081325 and causal gene CCR1 for rs33998492 (Supplemental Method S1). 378

Furthermore, the index SNP of rs505922 ($P = 2.24 \times 10^{-9}$) in the 9q34.2 locus is highly LD with 379 the reported SNP of rs657152 ($R^2 = 0.874$) [27] and rs8176719 ($R^2 = 0.876$) [25]. Based on the top-380 ranked V2G score for rs505922, we prioritized ABO as a potential causal gene contributing 381 susceptibility to severe COVID-19. By performing a MAGMA gene-level association analysis, we 382 observed that 25 genes including CXCR6, CCR1, IFNAR2, IL10RB, and OAS1 were significantly 383 associated with severe COVID-19 (FDR < 0.05, Supplemental Figure S8 and Table S4). GWAS-384 based pathway enrichment analysis revealed that 19 biological pathways, including cytokine-385 386 cytokine receptor interaction, influenza A, and TNF signaling, were significantly associated with hospitalized COVID-19 (Supplemental Figure S9 and Table S5). 387

388

389 Integrative analysis of GWAS on severe COVID-19 with GTEx eQTL data

To obtain combined signals from multiple tissues [49], we leveraged S-MultiXcan to meta-390 analyze the tissue-specific associations from 49 tissues in GTEx (see Methods), which showed that 391 the genetically predicted expressions of 16 genes were significantly associated with severe COVID-392 393 19 (FDR < 0.05, Figure 2C and Supplemental Table S6). Of note, 14 of 16 genes (87.5%) were identified to be significant in MAGMA analysis (Supplemental Figure S10A-B). Through 394 conducting S-PrediXcan analysis of blood and lung tissues that were linked with SARS-CoV-2 395 infection, we found eight genes whose genetically-regulated expression were significantly 396 associated with severe COVID-19 (FDR < 0.05, Supplemental Table S7). Using in silico 397 permutation analysis, we further observed that there existed a high consistence among results from 398 MAGMA, S-PrediXcan, and S-MultiXcan analyses ($P < 1.0 \times 10^{-5}$, Supplemental Figure S11A-C). 399 The aforementioned multiple genomic analyses identified 34 risk genes that showed supportive 400 evidence of involvement in the etiology of COVID-19 (Supplemental Figure S12A-B). 401

402

403 Functional characterization of 34 risk genes for severe COVID-19

The result of a network-based enrichment analysis suggested that 22 of 34 risk genes were 404 significantly enriched in a PPI subnetwork ($P = 2.85 \times 10^{-13}$, Figure 2D), which is consistent with 405 the consensus that disease-related genes are more densely connected [50, 51]. To functionally 406 characterize the drug targets of these genes, we conducted a drug-gene interaction analysis and 407 identified 11 genes including CCR1, IFNAR2, IL10RB, and OAS1 were targeted by at least one 408 known drug (Figure 2D and Supplemental Figure S14), of which some genes including CCR1, 409 IFNAR2, and IL10RB have been reported to be drug targets for treating severe COVID-19 patients 410 411 [25, 26]. Furthermore, these 34 genes were significantly enriched in a functional module consisting 412 of 10 biological pathways (Figure 2E, Supplemental Table S8 and Figure S13), among which two

413 top-ranked ones being cytokine-cytokine receptor interaction and chemokine signaling pathway
414 (FDR < 0.05). Most of these enriched pathways have been reported to be implicated in COVID-19
415 [25, 52, 53].

Based on the expression profile of dataset #1, we conducted a hierarchical clustering analysis 416 of these identified risk genes on COVID-19 severity, and found that these risk genes predisposed 417 418 be highly-expressed in severe patients compared to normal group (Permuted P = 0.023, Figure 2F-G). Consistently, the number of significant enriched pathways were elevated with increased 419 severities (Figure 2H). Genes in both cytokine-cytokine receptor interaction and chemokine 420 signaling pathways showed significantly high expressions in the early phase of SARS-CoV-2 421 infection (Figure 2H), suggesting that these two pathways could play critical roles in the initiation 422 of COVID-19. 423

424

425 Genetics-influenced peripheral immune cell types for severe COVID-19

To identify genome-wide genetics-influenced immune cells for severe COVID-19, we first 426 leveraged a regression-based polygenic model to integrate GWAS summary data on severe 427 COVID-19 with single-cell transcriptomic profiles (dataset #1) according to different COVID-19 428 severities (See methods). We found that CD16+monocytes were significantly associated with three 429 phases of COVID-19, mature B cells showed remarkable associations with mild COVID-19, 430 megakaryocytes were significantly associated with moderate and severe COVID-19, and memory 431 CD8+T cells showed significant associations with severe COVID-19 (simulated P < 0.05, Figure 432 3A). Further, we used a generalized linear regression model to validate these severe COVID-19-433 associated cell types by conditioning on the 10% most specific genes for each type, and consistently 434 found that CD16+monocytes and megakaryocytes showed notable associations with severe 435 436 COVID-19 (P < 0.05, Supplemental Method S2). These results indicated that CD16+monocytes,

437 megakaryocytes, and memory CD8+T cells were more vulnerable to the influence of genetic
438 components on severe-stage patients.

Based on the specificity algorithm used in MAGMA, we noticed that the top specific cell type 439 of CCR1 was CD16+monocytes, CXCR6 was most specifically expressed in memory CD8+T cells, 440 and ABO was specific to megakaryocytes (Supplemental Figure S15A), recalling that CXCR6, 441 442 CCR1 and ABO were prioritized to be candidate causal genes for severe COVID-19 based on the V2G score in above genetics-based analysis. Compared with other cell types, *CCR1* was primarily 443 expressed in CD16+monocytes (24.77%), CXCR6 was mainly expressed in memory CD8+T cells 444 (40.29%), and the ABO-expressed cells were highly specific to megakaryocytes (54.63%)445 (Supplemental Figure S15B and Table S9). To gather additional empirical support, we analyzed the 446 combined dataset of both datasets #2 and #3 as a validation and found CCR1, CXCR6, and ABO 447 showed a consistent specificity in the three cell types (Supplemental Figure S16). 448

Given that the primary goal of current study was to characterize genetics-influenced peripheral immune cell types for severe COVID-19, the majority of our subsequent detailed analyses would be concentrated on three immune cell subpopulations: $CCR1^+$ CD16+monocytes, ABO^+ megakaryocytes, and $CXCR6^+$ memory CD8+T cells (Figure 3B).

453

CCR1⁺ CD16+monocytes and ABO⁺ megakaryocytes contributing higher risk to cytokine storm 454 The accumulating lines of evidence [29, 54] have suggested that subsets of monocytes and 455 megakaryocytes might be the major resources of inflammatory storm. We sought to examine 456 whether CCR1⁺ CD16+monocytes and ABO⁺ megakaryocytes play more important roles in 457 cytokine storm among severe patients. As for CCR1+ CD16+monocytes, we found that the 458 inflammatory cytokine score was significantly higher than that of $CCRI^{-}$ CD16+monocytes (P = 459 2.5×10^{-7} , Figure 4A). Consistently, the combined score of both cytokine-cytokine receptor 460 461 interaction and chemokine signaling pathway was prominently higher in CCR1⁺ CD16+monocytes

 $(P < 2.2 \times 10^{-16})$, Supplemental Figure 17A). Compared with CCR1⁻ CD16+monocytes, there were 462 351 significantly highly-expressed genes in CCR1+ CD16+monocytes, such as inflammatory and 463 cytokine genes of IL1B, IL27, CXCL10, CXCL8, CD14, and OSM (FDR < 0.05, Figure 4B and 464 Supplemental Table S11), which have been documented to be associated with the inflammatory 465 response and chemotaxis of immune cells among COVID-19 patients [10, 15, 55, 56]. Functionally, 466 19 KEGG pathways were significantly overrepresented by the 351 highly-expressed genes (FDR <467 0.05, Figure 4C and Supplemental Table S12), including cytokine-cytokine receptor interaction and 468 chemokine signaling pathway, reminiscing that most of them were identified in above genetics-469 based pathway analysis. Additionally, these highly-expressed genes among $CCR1^+$ 470 CD16+monocytes have a remarkably higher proportion of druggable genes and COVID-19-471 associated druggable genes ($P \le 0.01$, Supplemental Figure S17 and Table S13). 472

The cell percentage of $CCR1^+$ CD16+monocytes showed a notable elevation among moderate 473 and severe patients compared with normal controls (P < 0.001), with no significant difference 474 between mild patients and normal controls (P = 0.1, Figure 4D). Furthermore, the inflammatory 475 cytokine scores among CCR1+ CD16+monocytes were significantly elevated with increased 476 severities (Trend P = 0.0013, Figure 4E). In comparison with normal controls, mild, moderate, and 477 478 severe patients displayed significantly up-regulated expressions (up-DEGs) with 14, 169, and 190 genes respectively (FDR < 0.05, Figure 4F and Supplemental Figure S17D). Notably, there existed 479 a high correlation between up-DEGs of moderate and severe patients (r = 0.937, P < 2.2×10^{-16} ; 480 Figure 4G), such as S100A8, S100A9, and IFITM1 (Figure 4H-4J), indicating a similar expression 481 pattern between moderate and severe patients. Accumulating release of massive amounts of 482 calprotectin (S100A8/S100A9) in monocytes contributes to inflammatory response among severe 483 COVID-19 patients [10, 16, 29]. 484

Furthermore, these 190 up-DEGs were significantly enriched in disease-terms associated with viral infection and inflammation and 17 functional GO-terms (FDR < 0.05, Figure 4K,

Supplemental Figure S17E and Tables S14-S15), including interferon alpha/beta signaling and 487 interferon gamma signaling. These interferon-related genes including IRF3, IRF2, IFI6, IFITM1, 488 ISG15, and ICAM1 may induce autoinflammatory and autoimmune conditions contributing to the 489 innate immune cells against SARS-CoV-2 infection [57, 58]. Of note, a high proportion of 63.68% 490 among 190 up-DEGs such as CXCL8, IFITM1, S100A8, and S100A9 were annotated into 15 491 492 potential druggable gene categories (Supplemental Figure S17F-L and Table S16). These results indicated that interferon-related genes among $CCR1^+$ CD16+monocytes have instrumental effects 493 in exacerbating inflammation among severe patients. 494

In addition, we found that ABO^+ megakaryocytes had a significantly higher inflammatory 495 cytokine score than that in ABO⁻ cells (P < 0.001, Supplemental Figure S18A-B). Compared with 496 ABO⁻ megakaryocytes, 424 genes were significantly highly-expressed in ABO^+ megakaryocytes 497 (FDR < 0.05, Supplemental Figure S18C and Table S17). These 424 highly-expressed genes were 498 significantly enriched in systemic lupus erythematosus, alcoholism, and platelet activation (FDR < 499 0.05, Supplemental Figure S18D and Table S18). Similar to CCR1⁺ CD16+monocytes, the cell 500 percentage of ABO⁺ megakaryocytes was significantly elevated among moderate and severe 501 patients (P < 0.01, Supplemental Figure S18E). Among ABO⁺ megakaryocytes, 20 and 35 up-DEGs 502 503 were notably associated with moderate and severe patients, respectively (FDR < 0.05, Supplemental Figure S18F-G). There was a highly overlapped rate of these up-DEGs between moderate and 504 severe COVID-19 groups, including ACP1, S100A8, and A100A9 (18/20 = 90%, Supplemental 505 Figure S18F-N). These 35 up-DEGs were annotated to 12 druggable gene categories and 506 significantly enriched in several disease terms (Supplemental Figure S18H and Tables S19-S20), 507 such as shock and thrombocytopenia, which were reported to be associated with COVID-19 [59]. 508 Overall, these results suggest that both $CCR1^+$ CD16+monocytes and ABO^+ megakaryocytes 509 510 contribute higher risk to inflammatory storm among severe patients.

511

512 CXCR6⁺ memory CD8+T cells convey risk to severe COVID-19

Earlier studies [10, 60] have indicated that polyfunctional T cells play important roles in 513 dominating the anti-viral infection immune response and can release a substantially higher amount 514 of multiple distinct cytokines and chemokines in comparison to other T cells. It is plausible to infer 515 that there exist subsets of memory CD8+T cells predisposing to be multi-functional for against 516 517 SARS-CoV-2 infection. We calculated several immunological features to evaluate whether *CXCR6*⁺ memory CD8+T cells have a higher polyfunctionality than *CXCR6*⁻ memory CD8+T cells. 518 Compared with CXCR6⁻ memory CD8+T cells, we found that scores of cytokine, chemokine, IFN-519 α/β response. T cell activation, proliferation, and migration were significantly higher among 520 $CXCR6^+$ memory CD8+T cells (P < 0.05, Figure 5A-D and Supplemental Figure S19A-C). There 521 were 158 highly-expressed genes among $CXCR6^+$ memory CD8+T cells in comparison with 522 $CXCR6^{-}$ cells (FDR < 0.05, Figure 5E). These highly-expressed genes were significantly enriched 523 in two biological pathways of cytokine-cytokine receptor interaction and inflammatory bowel (FDR 524 < 0.05, Supplemental Figure S19D and Table S21). The chemokine signaling pathway showed a 525 suggestive enrichment (P < 0.05). These highly-expressed genes contained numerous pro-526 inflammatory cytokine and chemokine genes, such as CCR1, CCR2, CCR5, CCR6, CCL3L1, 527 IFNGR1, IL18R1, IL23R, MYC, and TNFSF14, which may be associated with the activation of 528 memory CD8+T cells. 529

Furthermore, the cell proportion of *CXCR6*⁺ memory CD8+T cells was significantly higher among both mild and moderate COVID-19 than that among normal group (P < 0.05), whereas the cell proportion of *CXCR6*⁺ memory CD8+T cells among severe COVID-19 was remarkably lower than that among normal group (P = 0.012, Figure 5F). Consistently, we found that the scores of chemokine, T cell activation, and migration were increased with the increasing patient severities among *CXCR6*⁺ memory CD8+T cells (Trend P < 0.05, Figure 5G-I), and that lower cytotoxicity score and exhaustion score were observed among moderate-to-severe patients (Trend P < 0.05,

537	Supplemental Figure S19E-F). Additionally, we found 44, 42, and 53 up-DEGs that were notably
538	associated with mild, moderate, and severe COVID-19, and there were six significant common
539	genes across three phases of COVID-19, including TCF7, GZMH, RAB5IF, CCND2, BIRC6, and
540	NDUFAF3 (Figure 5J-K and Supplemental Figure S19G-N). The gene of TCF7 was an essential
541	factor in memory CD8+T cell differentiation [61], and GZMH was reported to mediate antiviral
542	activity through direct cleavage of viral substrates [62]. These 108 up-DEGs were found to be
543	significantly enriched in 22 functional GO-terms, including Fc-gamma receptor signaling pathway,
544	regulation of leukocyte differentiation, and activation of immune response (Figure 5L-M and
545	Supplemental Table S22). Overall, these results indicated that <i>CXCR6</i> ⁺ memory CD8+T cells have
546	an enhanced propensity to be multi-functional and activated T cells involved in severe COVID-19.

547

548 Elevated cellular interactions may enhance the resident to lung airway for COVID-19

To gain refined insights into $CCR1^+$ CD16+monocytes and $CXCR6^+$ memory CD8+T cells, we 549 examined the cellular interactions among cell populations in PBMCs and BALFs according to the 550 COVID-19 disease status using the CellChat algorithm [47]. For CCR1⁺ CD16+monocytes in 551 PBMCs, we found a notable increase in cell-to-cell interactions with other immune cells among 552 severe patients than that in normal controls (P < 0.05, Figure 6A and Supplemental Figure S20). 553 There was no statistical difference in cellular communications of CCR1⁻ CD16+monocytes with 554 other cells between normal and COVID-19 patients (P > 0.05, Figure 6B). Compared with normal 555 controls, CCR1⁺ CD16+monocytes showed elevated interactions with megakaryocytes, memory 556 CD8+T cells, NK, effector CD8+T cells, and CD14+monocytes among severe patients 557 (Supplemental Figure S20). There were 14 ligand-receptor interactions observed to be remarkably 558 dominated among severe patients (Figure 6C), including ANXA1-FPR1, ITGB2-ICAM2/CD226, 559 560 LGALS9-CD44, SELPLG-SELL/SELP, APP-CD74, and THBS1-CD36/CD47.

With regard to CXCR6⁺ memory CD8+T cells in PBMCs, the predicted cell-to-cell interactions 561 showed a prominent elevation with increased severities of COVID-19 (P < 0.05, Figure 6D). 562 Similar to CCR1⁻ CD16+monocytes, we observed no obvious difference of cellular interactions 563 between normal controls and COVID-19 patients among $CXCR6^{-}$ memory CD8+T cells (P > 0.05, 564 Figure 6E). Compared with healthy individuals, $CXCR6^+$ memory CD8+T cells demonstrated 565 higher cellular communications with CD14+monocytes, CD34+progenitors, dendritic cells, 566 effector CD8+T cells, na ve CD8+T cells, memory CD4+T cell, na ve CD4+T cells, NK, and 567 megakaryocytes among severe patients (Supplemental Figure S20). There were 20 elevated cellular 568 interactions of CXCR6⁺ memory CD8+T cells with other immune cells among severe patients, 569 including ADGRE5-CD55, ANXA1-FPR1, CCL3/CCL5-CCR1, CD99-CD99/PILRA, ICAM2-570 (ITGAL+ITGB2), and ITGB2-ICAM2/CD226 (Figure 6F). These cell adhesion molecules (ANXA1 571 and ICMA2), cytokine binding and receptor activity genes (CD44, CD36, CD74, CXCR4, and 572 THBS1), and inflammatory genes (FPR1 and SELL) have been reported to be associated with 573 574 COVID-19 [16, 55, 63, 64].

Among BALF cells, we also observed a remarkable increase in cellular interactions of $CCR1^+$ 575 CD16+monocytes and $CXCR6^+$ memory CD8+T cells comparing to their corresponding negative 576 cells (P < 0.001, Figure 6G-J and Supplemental Figure S21A). For example, enhanced ligand-577 receptor axes of SELPLG-SELL, CCL5-CCR1, FN1-(ITGA4+ITGB1), CD99-CD99, and APP-578 CD74 among CCR1⁺ CD16+monocytes (Figure 6H), as well as CXCL16-CXCR6, TNFSF14-579 TNFRSF14, ITGB2-CD226, CLEC2B/CLEC2C-KLRB1, and CCL3/CCL4-CCR5 among CXCR6⁺ 580 memory CD8+T cells (Figure 6J). Notably, there was a 60% increase in cellular interactions 581 between $CCR1^+$ CD16+monocytes and epithelial cells compared with that of $CCR1^-$ 582 CD16+monocytes (Supplemental Figure S21B). We also found a 33.33% increase in the 583 584 interactions between $CXCR6^+$ memory CD8+T cells and epithelial cells compared with that of CXCR6⁻ memory CD8+T cells (Supplemental Figure S21C), such as enhanced ligand-receptor 585

interactions including *TNF-TNFRSF1A*, *CXCL16-CXCR6*, and *CCL3-CCR5*. Previous studies [65,
66] have reported that the *CXCL16-CXCR6* axis modulates the localization of tissue-resident
memory CD8+T cells to the lung airway. Overall, these results suggest that the increased cellular
interactions with epithelial cells probably enhance the resident to the lung airway for against SARSCoV-2 infection.

- 591
- 592

Discussion

By using large-scale genetics data, we identified eight genomic loci including three novel loci 593 (e.g., 1p22.2, 6p21.33, and 7p11.2) that were significantly associated with severe COVID-19. Other 594 five loci including 3p21.31, 9q34.2, 12q24.13, 19p13.3, and 21q22.11 have been reported to be 595 involved in COVID-19 risk in previous studies [23-28]. Notably, we prioritized 34 risk genes, 596 597 including potential causal genes of CXCR6, CCR1, and ABO, to be associated with severe COVID-19. The CXC motif chemokine receptor 6 (CXCR6), which is a G protein-coupled receptor with 598 seven transmembrane domains, regulates the partitioning of resident memory T cells by recruiting 599 lung tissue-resident memory CD8+T cells to airways [65]. CCR1 gene encodes the CC motif 600 chemokine receptor 1 (CCR1) belonging to a member of the beta chemokine receptor family. 601 Several previous GWASs have reported genetic variants in CCR1 are associated with COVID-19 602 susceptibility at a genome-wide significant level [25, 27]. For the ABO gene, it encodes protein 603 relevant to the ABO blood group system. Both genetic and non-genetic studies [25, 27, 67] have 604 605 showed the involvement of ABO gene in COVID-19 susceptibility, while the ABO gene encodes protein that is relevant to the ABO blood group system, and it was also notably associated with 606 several thrombotic and coagulation-related traits including deep vein thrombosis and pulmonary 607 heart disease, which have been reported to be risk factors and sequalae to severe COVID-19 [68, 608 69]. 609

610 Understanding the immune responses of monocytes and memory T cells is fundamental to the rational design of innovative and effective strategies to develop better vaccines [70, 71], and 611 contributes to reveal the pathogenesis of severe COVID-19 [29]. Our current analyses reveal that 612 host genetic determinants have a prominent influence on the immune responses of 613 CD16+monocytes, megakaryocytes, and memory CD8+T cells to severe COVID-19. Previous 614 615 studies [11, 29, 54] showed that the influence caused by monocytes and megakaryocytes in inflammatory storms is noteworthy among severe COVID-19 patients. We found that $CCR1^+$ 616 CD16+monocytes and ABO^+ megakaryocytes showed a significantly increased propensity to cause 617 inflammatory storms among severe patients. The observations suggest highly-expressed interferon-618 related genes, including S100A8, S100A9, S100A12, CD14, CXCL8, IGSF6, IRF3, IFI6, IFITM1, 619 and IFITM3 among the two cell subsets contribute to exacerbate inflammation among severe 620 patients. The inflammatory mediator of EN-RAGE encoded by S100A12 was significantly 621 correlated with COVID-19 [21], and S100A8, S100A9, IRF3, IF16, IF1TM1, and IF1TM3 have been 622 reported to elicit autoinflammatory and autoimmune conditions in response to SARS-CoV-2 623 infection [10, 16, 29, 57, 58]. Double positive CD14+CD16+monocytes reported as tissue-624 infiltrative cells have a higher potency of antigen presentation and highly-expressed 625 proinflammatory cytokines [72, 73]. Additionally, interferons are the mediators in several canonical 626 host antiviral signaling to activate the expression of numerous required molecules of the early 627 response to viral infection [74], and impaired type I interferon activity play important roles in severe 628 COVID-19 [58]. Our findings described above suggest that CCR1+ CD16+monocytes and ABO+ 629 megakaryocytes as a functional subset of myeloid cells convey higher risks to severe COVID-19. 630

Memory CD8+T cells could elicit improved immunological features that are critical in host protection from viral infectious [71]. After influenza virus infections, memory CD8+T cells reside in the lung for a couple of months and these resident memory T cells are necessary for effective immunity against secondary infection [75]. Among severe COVID-19 patients, we found that

CXCR6⁺ memory CD8+T cells undertook several improved immunological features, including 635 higher scores of cytokine, chemokine, T cell activation, proliferation, and migration, which 636 suggests CXCR6⁺ memory CD8+T cells potentially contribute to the protection of SARS-CoV-2 637 infection. Among these positive $CXCR6^+$ cells, numerous highly-expressed cytokine and 638 chemokine genes, including CCR1, CCR2, IFNGR1, and MYC, may work on activating memory T 639 cells. Earlier evidence indicated that MYC was rapidly but temporally induced during the early 640 stage of T cell activation [76]. The CCR1 plays a pivotal role in the recruitment of effector immune 641 cells to the site of inflammation, and the pharmacologic inhibition of this gene may suppress 642 immune hyper-activation in severe COVID-19 [15]. Memory CD8+T cells obtained the capability 643 of transforming to effector cells by sensing inflammation from monocytes [71]. Thus, inflammatory 644 $CCR1^+$ CD16+monocytes among severe COVID-19 patients potentially accelerate the activation 645 of memory CD8+T cells. 646

Additionally, we observed a prominent decrease of the cell proportion of $CXCR6^+$ memory 647 CD8+T cells among severe patients. This decrease in peripheral blood among severe patients is 648 probably due to efflux to the site of viral infected lung tissue in answer to ongoing tissue damage. 649 Earlier studies [29, 77] have reported that functional CD8+T cell subsets manifest a notable 650 decrease in the peripheral blood of severe COVID-19 patients. Epithelium is the most vulnerable 651 tissue to be attacked by viral or microbial infection, thus the presence of resident memory CD8+T 652 cells are imperative for defending the debilitating infections for hosts [75]. In the current study, we 653 found an obvious increase in cellular interactions of CXCR6⁺ memory CD8+T cells with 654 epitheliums. Enhanced ligand-receptor interactions including TNF-TNFSFRSF1A, CXCL16-655 CXCR6, and CCL3-CCR5 may contribute to the lung-residence of memory CD8+T cells. Previous 656 evidence demonstrated a major role for CXCL16-CXCR6 interactions in regulating the resident of 657 658 virus-specific memory CD8+T cells [65, 66]. An earlier study showed a stronger interactions between epithelial and immune cells among severe COVID-19 cases than that among moderate 659

cases [15]. We demonstrated that $CXCR6^+$ memory CD8+T cells mounted highly effective immune responses to against COVID-19, highlighting the remarkable biological plasticity in subsets of memory CD8+T cells differentiation.

The power of this study is limited by the lack of matched genetic data and scRNA-seq data in 663 each sample for uncovering the genetic effects on immune cells for severe COVID-19. To reduce 664 the influence of this limitation, we adopted a widely-used approach by integrating a large-scale 665 GWAS summary statistics with enormous amount of single cell sequencing data, as referenced in 666 previous studies [45, 78]. Based on our findings suggesting that host genetic components exert 667 regulatory effects on immunological dysregulations for SRAS-CoV-2 infection, more studies are 668 warranted for exploring the genetic modification of peripheral T cells to defend against lethal severe 669 COVID-19. 670

671

672 **Conclusions**

In sum, we provide comprehensive insights that host genetic determinants are fundamental in influencing the peripheral immune responses to severe COVID-19. Both $CCR1^+$ CD16+monocytes and ABO^+ megakaryocytes contribute higher risk to the inflammatory storms among severe patients. $CXCR6^+$ memory CD8+T cells exhibit a notable polyfunctionality of several improved immunologic features implicated in the etiology of severe COVID-19. Further experiments to parse the molecular mechanism of these three cell subpopulations on severe COVID-19 patients are crucial for promoting personalized protective immunity.

680

681 Abbreviations

COVID-19: coronavirus disease 2019; SARS-CoV-2: severe acute respiratory syndrome
coronavirus 2; GWAS: genome-wide association study; scRNA-seq: single cell RNA sequencing;
PBMCs: peripheral blood mononuclear cells; BALF: bronchoalveolar lavage fluid; eQTL:

685	expression quantitative trait loci; GEO: the Gene Expression Omnibus database; WHO: the World
686	Health Organization; SNP: single nucleotide polymorphism; OR: odds ratio; MAF: minor allele
687	frequency; QQ: quantile-quantile; MAGMA: Multi-marker Analysis of GenoMic Annotation; LD:
688	linkage disequilibrium; FDR: false discovery rate; KEGG: the Kyoto Encyclopedia of Genes and
689	Genomes; PPC: the Pearson correlation coefficient; MDS: multidimensional scaling; OTG: the
690	Open Target Genetics; PPI: protein-protein interaction; up-DEG: significantly up-regulated
691	expression gene associated with COVID-19.

- 692
- 693 **Declarations**

694 Acknowledgments

We appreciate Prof. Yang Jian from Westlake University for providing helpful suggestions, and our appreciation also goes to all the authors from the COVID-19 Host Genetic Consortium who have deposited and shared GWAS summary data on public databases and goes to the authors who publicly released the scRNA-seq datasets on PBMC and BALF with distinct COVID-19 severities.

700 Authors' contributions

J.S., and Y.M. conceived and designed the study. Y.M., F.Q., C.D., J.L., Y.K.H., Y.R.Z., Y.X.,

702 Y.G.Z., and Y.H.Y. contributed to management of data collection. Y.M., F.Q., C.D., Y.K.H., and

J.L. conducted bioinformatics analysis and data interpretation. Y.M., J.S., Z.W. and J.Q. wrote the
 manuscripts. All authors reviewed and approved the final manuscript.

705

706 Funding

This study was funded by the National Natural Science Foundation of China (61871294 to J.S.),

the Scientific Research Foundation for Talents of Wenzhou Medical University (KYQD20201001

to Y.M.), and Science Foundation of Zhejiang Province (LR19C060001 to J.S).

710

711 **Data and materials availability:**

712	All the GWAS summary statistics used in this study can be accessed in the official websites			
713	(www.covid19hg.org/results). The GTEx eQTL data (version 8) were downloaded from Zenodo			
714	repository (https://zenodo.org/record/3518299#.Xv6Z6igzbgl). Three scRNA-seq datasets were			
715	downloaded from the GEO database (https://www.ncbi.nlm.nih.gov/gds/?term=GSE149689 and			
716	https://www.ncbi.nlm.nih.gov/gds/?term=GSE150861) and the ArrayExpress database			
717	(https://www.ebi.ac.uk/arrayexpress/experiments/E-MTAB-9357). All analysis code in the			
718	Methods is available in an online GitHub repository at			
719	https://github.com/mayunlong89/COVID19_scRNA.			
720				
721	Ethics approval and consent to participate			
722	Not applicable			
723				
724	Consent for publication			
725	Not applicable			
726				
727	Competing interests:			
728	The authors declare no competing interests.			
729				
730	Figure Legends			
731	Figure 1. The workflow for this integrative genomic analysis. A) Combination of single cell			
732	RNA sequencing data and GWAS summary statistics on severe COVID-19 based on two			
733	independent methods. One method is regression-based polygenic model based on whole scRNA-			
734	seq profiles, and another is generalized linear regression model based on top 10% most specific			

- genes for each cell type. B) An increase in genetics-risk genes and cytokines for severe COVID-19.
- C) Cellular interaction analysis of genetics-influenced immune cell subsets with epithelial cells.
- 737

Figure 2. Risk genes and pathways associated with hospitalized COVID-19 from meta-GWAS 738 summary data. A) Manhattan plot and quantile-quantile (QQ) plot of meta-GWAS analysis 739 highlighting eight risk genetic loci for hospitalized COVID-19. The red horizontal line represents 740 the genome-wide significance threshold of P < 5×10^{-8} . The genomic inflation factor $\lambda = 1.02$. B) 741 Nine index SNPs within eight genomic loci associated with hospitalized COVID-19. Left panel 742 743 shows the P value of each index SNP, and right panel shows the odds ratio with 95% confidence interval. C) Circus plot showing the results of S-MultiXcan-based analysis. The inner ring 744 demonstrates the 22 autosomal chromosomes (Chr1-22). In the outer ring, a circular symbol 745 represents a specific gene and color marks the statistical significance of the gene for hospitalized 746 COVID-19 (Red marks FDR < 0.05, orange indicates $6.96 \times 10^{-5} \le P \le 0.001$, light blue marks 0.001 747 \leq P \leq 0.05, and dark blue indicates P > 0.0). D) PPI network of these 34 identified risk genes based 748 on the STRING database (v11.0, https://string-db.org/). Orange ring represents druggable genes 749 targeted by at least one known drug. E) Network module constructed by using the Jaccard distance 750 751 showing the connectivity of 10 significant pathways enriched by 34 risk genes. F) Heatmap showing the results of hierarchical clustering analysis of 27 risk genes on COVID-19 severity. 752 Seven risk genes did not expressed in the dataset #1, and the expression level of each gene was 753 754 scaled. G) The proportion of highly-expressed genes among 27 risk genes in normal controls and in the three phases of COVID-19 (mild, moderate, and severe patients). Using 10,000 times of 755 permutation analysis to calculate the significance of the observation (permuted P = 0.023). H) Plot 756 showing an increase of the significantly enriched pathways in the network module with elevated 757 758 COVID-19 severities. Orange color represents a significant enriched pathway (FDR ≤ 0.05) and gray color represents a non-significant enriched pathway (FDR > 0.05). 759

760

761	Figure 3. Integrative analysis identifies genetic associations between peripheral immune cells
762	and severe COVID-19. A) Bar graph showing the results of the combination of scRNA-seq data
763	and GWAS summary statistics on severe COVID-19 based on the RolyPoly among normal controls
764	and patients with different severities (i.e., mild, moderate, and severe). The y-axis shows the 13 cell
765	types, and x-axis shows mean negative log-transformation P value (-Log2(P)). Orange color
766	indicates a cell type showing a significant association, and light blue represents there is no
767	significant association. B) UMAP projections of peripheral immune cells colored by annotated cell
768	types. The plot showing the region of CD16+monocytes, megakaryocytes, and memory CD8+T
769	cells. Red dot represents positive gene expressions of CCR1 ⁺ , ABO ⁺ , and CXCR6 ⁺ , and gray stands
770	for negative cells.

771

Figure 4. *CCR1*⁺ CD16+momocytes contributes higher risk to cytokine storms among severe 772 **COVID-19 patients.** A) Boxplot showing the difference in inflammatory cytokine score between 773 CCR1⁺ and CCR1⁻ CD16+ monocytes. Two-side Wilcoxon sum-rank test was used. B) Volcano 774 plot showing differentially expressed genes between *CCR1*⁺ and *CCR1*⁻ CD16+ monocytes. C) 775 776 Significantly enriched pathways by 351 highly-expressed genes among $CCR1^+$ CD16+ monocytes. Color legend represents the log transformed FDR value (-Log10(FDR)). D) Bar graph showing the 777 proportion of *CCR1*⁺ CD16+ monocytes among normal, mild, moderate, and severe groups. E) 778 779 Boxplot showing the inflammatory cytokine score of *CCR1*⁺ CD16+ monocytes among normal, mild, moderate, and severe groups. The Mann-Kendall trend analysis was used. F) Bar graph 780 showing the differentially up-DEGs among different COVID-19 patients compared with normal 781 controls. Namely, mild COVID-19 vs. normal, moderate COVID-19 vs. normal, and severe 782 783 COVID-19 vs. normal. Venn plot on top of bar showing the overlapped up-DEGs between moderate and severe patients. G) The correlation of up-DEGs between moderate and severe patients. Pearson 784

correlation analysis was used to calculate the correlation coefficient and P value. H)-J)
Representative up-DEGs among *CCR1*⁺ CD16+ monocytes showing significantly elevated
expressions with increased COVID-19 severities. H) *S100A8*, I) *S100A9*, and J) *IFITM1*. K)
Disease-terms enrichment analysis on 190 up-DEGs based on the GLAD4U database. The y-axis
shows -Log10(FDR), and x-axis shows the enrichment ratio.

790

Figure 5. Multi-functionality of *CXCR6*⁺ memory CD8+T cells for severe COVID-19. A)-D) 791 Boxplots showing the difference in (A) cytokine score, (B) chemokine score, (C) IFN- α/β response 792 793 score, and (D) T cell activation score between CXCR6⁺ and CXCR6⁻ memory CD8+T cells. Twoside Wilcoxon sum-rank test was used. E) Volcano plot showing differentially expressed genes 794 between $CXCR6^+$ and $CXCR6^-$ memory CD8+T cells. F) Bar graph showing the proportion of 795 796 CXCR6⁺ memory CD8+T cells among normal, mild, moderate, and severe groups. G)-I) Boxplots showing the (G) chemokine score, (H) T cell activation score, and (I) migration score of $CXCR6^+$ 797 memory CD8+T cells among normal, mild, moderate, and severe groups. The Mann-Kendall trend 798 analysis was used. J) Venn plot showing the overlapped up-DEGs between pairwise comparisons: 799 mild vs. normal, moderate vs. normal, and severe vs. normal. K) Representative gene of GZMH 800 among CXCR6⁺ memory CD8+T cells showing significantly elevated expressions with increased 801 COVID-19 severities. L) Heatmap showing up-DEGs in CXCR6⁺ memory CD8+T cells from 802 pairwise comparisons: mild vs. normal, moderate vs. normal, severe vs. normal. The up-DEGs 803 804 listed in the green panel were from mild vs. normal, yellow panel were from moderate vs. normal, and orange panel were from severe vs. normal. M) Scatter plot showing the enriched GO biological 805 processes by 108 up-DEGs among $CXCR6^+$ memory CD8+T cells. The x-axis shows -Log10(FDR), 806 and y-axis shows the enrichment ratio. 807

808

809	Figure 6. Cell-to-cell interactions of <i>CCR1</i> ⁺ CD16+momocytes and <i>CXCR6</i> ⁺ memory CD8+T
810	cells with other cells in PBMC and BALF. A)-B) Boxplot showing the number of cellular
811	interactions of (A) CCR1 ⁺ CD16+ monocytes and (B) CCR1 ⁻ CD16+ monocytes with other immune
812	cells in PBMC between normal controls and patients with increased COVID-19 severities. C)
813	Predicted cellular interactions of CCR1 ⁺ CD16+ monocytes with other immune cells in PBMC,
814	comparing severe COVID-19 vs. normal control. D)-E) Boxplot showing the number of cellular
815	interactions of (D) CXCR6 ⁺ memory CD8+T cells and (E) CXCR6 ⁻ memory CD8+T cells with other
816	immune cells in PBMC between normal controls and patients with increased COVID-19 severities.
817	F) Predicted cellular interactions of $CXCR6^+$ memory CD8+T cells with other immune cells in
818	PBMC, comparing severe COVID-19 vs. normal control. G) Boxplot showing an increase in
819	cellular interactions with other cells in BALF for CCR1 ⁺ CD16+ monocytes than CCR1 ⁻ CD16+
820	monocytes. H) Predicted cellular interactions with other cells in BALF, comparing CCR1 ⁺ CD16+
821	monocytes with CCR1 ⁻ CD16+ monocytes. I) Boxplot showing an increase in cellular interactions
822	with other cells in BALF for <i>CXCR6</i> ⁺ memory CD8+T cells than <i>CXCR6</i> ⁻ memory CD8+T cells.
823	J) Predicted cellular interactions with other cells in BALF, comparing CXCR6 ⁺ memory CD8+T
824	cells with CXCR6 ⁻ memory CD8+T cells. The circular size represents the significance of each
825	ligand-receptor axis, and color represents the communication probability.

826

827 **References**

- Bong E, Du H, Gardner L: An interactive web-based dashboard to track COVID-19 in real time. Lancet Infect Dis 2020, 20:533-534.
 Wu Z, McGoogan JM: Characteristics of and Important Lessons From the Coronavirus
- Wu Z, McGoogan JM: Characteristics of and Important Lessons From the Coronavirus
 Disease 2019 (COVID-19) Outbreak in China: Summary of a Report of 72 314 Cases
 From the Chinese Center for Disease Control and Prevention. JAMA 2020.
- 833 3. Berlin DA, Gulick RM, Martinez FJ: Severe Covid-19. *N Engl J Med* 2020.
- Richardson S, Hirsch JS, Narasimhan M, Crawford JM, McGinn T, Davidson KW, Barnaby
 DP, Becker LB, Chelico JD, Cohen SL, et al: Presenting Characteristics, Comorbidities,
 and Outcomes Among 5700 Patients Hospitalized With COVID-19 in the New York
 City Area. JAMA 2020, 323:2052-2059.

- S. Guan WJ, Ni ZY, Hu Y, Liang WH, Ou CQ, He JX, Liu L, Shan H, Lei CL, Hui DSC, et al: Clinical Characteristics of Coronavirus Disease 2019 in China. *N Engl J Med* 2020, 382:1708-1720.
- Ku L, Ma Y, Yuan J, Zhang Y, Wang H, Zhang G, Tu C, Lu X, Li J, Xiong Y, et al: COVID-**19 Quarantine Reveals That Behavioral Changes Have an Effect on Myopia Progression.** *Ophthalmology* 2021.
- 7. Pedersen SF, Ho YC: **SARS-CoV-2: a storm is raging.** *J Clin Invest* 2020, **130:**2202-2205.
- Takahashi T, Ellingson MK, Wong P, Israelow B, Lucas C, Klein J, Silva J, Mao T, Oh JE,
 Tokuyama M, et al: Sex differences in immune responses that underlie COVID-19
 disease outcomes. *Nature* 2020, 588:315-320.
- 848
 9. Chen G, Wu D, Guo W, Cao Y, Huang D, Wang H, Wang T, Zhang X, Chen H, Yu H, et
 849
 849 al: Clinical and immunological features of severe and moderate coronavirus disease
 850
 2019. J Clin Invest 2020, 130:2620-2629.
- 851 10. Su Y, Chen D, Yuan D, Lausted C, Choi J, Dai CL, Voillet V, Duvvuri VR, Scherler K,
 852 Troisch P, et al: Multi-Omics Resolves a Sharp Disease-State Shift between Mild and
 853 Moderate COVID-19. Cell 2020, 183:1479-1495.e1420.
- Biggin State
 Biggin State<
- Ren X, Wen W, Fan X, Hou W, Su B, Cai P, Li J, Liu Y, Tang F, Zhang F, et al: COVID-**19 immune features revealed by a large-scale single-cell transcriptome atlas.** *Cell* 2021.
- Wen W, Su W, Tang H, Le W, Zhang X, Zheng Y, Liu X, Xie L, Li J, Ye J, et al: Immune
 cell profiling of COVID-19 patients in the recovery stage by single-cell sequencing. *Cell Discov* 2020, 6:31.
- 862 14. Zhang JY, Wang XM, Xing X, Xu Z, Zhang C, Song JW, Fan X, Xia P, Fu JL, Wang SY,
 863 et al: Single-cell landscape of immunological responses in patients with COVID-19. Nat
 864 Immunol 2020, 21:1107-1118.
- 15. Chua RL, Lukassen S, Trump S, Hennig BP, Wendisch D, Pott F, Debnath O, Th ürmann L,
 Kurth F, V ölker MT, et al: COVID-19 severity correlates with airway epitheliumimmune cell interactions identified by single-cell analysis. Nat Biotechnol 2020, 38:970979.
- 869 16. Silvin A, Chapuis N, Dunsmore G, Goubet AG, Dubuisson A, Derosa L, Almire C, H énon
 870 C, Kosmider O, Droin N, et al: Elevated Calprotectin and Abnormal Myeloid Cell
 871 Subsets Discriminate Severe from Mild COVID-19. *Cell* 2020, 182:1401-1418.e1418.
- Schulte-Schrepping J, Reusch N, Paclik D, Baßler K, Schlickeiser S, Zhang B, Krämer B,
 Krammer T, Brumhard S, Bonaguro L, et al: Severe COVID-19 Is Marked by a
 Dysregulated Myeloid Cell Compartment. *Cell* 2020, 182:1419-1440 e1423.
- 18. Lee JS, Park S, Jeong HW, Ahn JY, Choi SJ, Lee H, Choi B, Nam SK, Sa M, Kwon JS, et
 al: Immunophenotyping of COVID-19 and influenza highlights the role of type I
 interferons in development of severe COVID-19. *Sci Immunol* 2020, 5.
- 878 19. Cao X: COVID-19: immunopathology and its implications for therapy. Nat Rev
 879 Immunol 2020, 20:269-270.
- 20. Del Valle DM, Kim-Schulze S, Huang HH, Beckmann ND, Nirenberg S, Wang B, Lavin Y,
 Swartz TH, Madduri D, Stock A, et al: An inflammatory cytokine signature predicts
 COVID-19 severity and survival. *Nat Med* 2020, 26:1636-1643.
- Arunachalam PS, Wimmers F, Mok CKP, Perera R, Scott M, Hagan T, Sigal N, Feng Y,
 Bristow L, Tak-Yin Tsang O, et al: Systems biological assessment of immunity to mild
 versus severe COVID-19 infection in humans. *Science* 2020, 369:1210-1220.

- The COVID-19 Host Genetics Initiative, a global initiative to elucidate the role of host
 genetic factors in susceptibility and severity of the SARS-CoV-2 virus pandemic. *Eur J Hum Genet* 2020, 28:715-718.
- Zhou S, Butler-Laporte G, Nakanishi T, Morrison DR, Afilalo J, Afilalo M, Laurent L,
 Pietzner M, Kerrison N, Zhao K, et al: A Neanderthal OAS1 isoform protects individuals
 of European ancestry against COVID-19 susceptibility and severity. *Nat Med* 2021,
 27:659-667.
- Pairo-Castineira E, Clohisey S, Klaric L, Bretherick AD, Rawlik K, Pasko D, Walker S,
 Parkinson N, Fourman MH, Russell CD, et al: Genetic mechanisms of critical illness in
 COVID-19. *Nature* 2021, 591:92-98.
- Ma Y, Huang Y, Zhao S, Yao Y, Zhang Y, Qu J, Wu N, Su J: Integrative Genomics
 Analysis Reveals a 21q22.11 Locus Contributing Risk to COVID-19. *Hum Mol Genet* 2021.
- 899 26. Gaziano L, Giambartolomei C, Pereira AC, Gaulton A, Posner DC, Swanson SA, Ho YL,
 900 Iyengar SK, Kosik NM, Vujkovic M, et al: Actionable druggable genome-wide
 901 Mendelian randomization identifies repurposing opportunities for COVID-19. Nat
 902 Med 2021, 27:668-676.
- 27. Ellinghaus D, Degenhardt F, Bujanda L, Buti M, Albillos A, Invernizzi P, Fern ández J, Prati
 D, Baselli G, Asselta R, et al: Genomewide Association Study of Severe Covid-19 with
 Respiratory Failure. N Engl J Med 2020, 383:1522-1534.

906 28. Mapping the human genetic architecture of COVID-19. *Nature* 2021.

- P07 29. Ren X, Wen W, Fan X, Hou W, Su B, Cai P, Li J, Liu Y, Tang F, Zhang F, et al: COVIDP08 19 immune features revealed by a large-scale single-cell transcriptome atlas. *Cell* 2021,
 P09 184:1895-1913.e1819.
- Butler A, Hoffman P, Smibert P, Papalexi E, Satija R: Integrating single-cell
 transcriptomic data across different conditions, technologies, and species. *Nat Biotechnol* 2018, 36:411-420.
- 31. Waltman L, van Eck NJ: A smart local moving algorithm for large-scale modularitybased community detection. *The European Physical Journal B* 2013, 86:471.
- 32. Korsunsky I, Millard N, Fan J, Slowikowski K, Zhang F, Wei K, Baglaenko Y, Brenner M,
 Loh PR, Raychaudhuri S: Fast, sensitive and accurate integration of single-cell data with
 Harmony. Nat Methods 2019, 16:1289-1296.
- 33. Auton A, Brooks LD, Durbin RM, Garrison EP, Kang HM, Korbel JO, Marchini JL,
 McCarthy S, McVean GA, Abecasis GR: A global reference for human genetic variation. *Nature* 2015, **526**:68-74.
- 921 34. Pruim RJ, Welch RP, Sanna S, Teslovich TM, Chines PS, Gliedt TP, Boehnke M, Abecasis
 922 GR, Willer CJ: LocusZoom: regional visualization of genome-wide association scan
 923 results. *Bioinformatics* 2010, 26:2336-2337.
- 35. de Leeuw CA, Mooij JM, Heskes T, Posthuma D: MAGMA: generalized gene-set
 analysis of GWAS data. *PLoS Comput Biol* 2015, 11:e1004219.
- 36. Wang J, Duncan D, Shi Z, Zhang B: WEB-based GEne SeT AnaLysis Toolkit
 (WebGestalt): update 2013. Nucleic Acids Res 2013, 41:W77-83.
- 37. Kanehisa M, Goto S: KEGG: kyoto encyclopedia of genes and genomes. *Nucleic Acids Res* 2000, 28:27-30.
- Ma Y, Li J, Xu Y, Wang Y, Yao Y, Liu Q, Wang M, Zhao X, Fan R, Chen J, et al:
 Identification of 34 genes conferring genetic and pharmacological risk for the
 comorbidity of schizophrenia and smoking behaviors. Aging (Albany NY) 2020,
 12:2169-2225.
- 39. Barbeira AN, Dickinson SP, Bonazzola R, Zheng J, Wheeler HE, Torres JM, Torstenson
 Barbeira AN, Dickinson SP, Bonazzola R, Zheng J, Wheeler HE, Torres JM, Torstenson
 ES, Shah KP, Garcia T, Edwards TL, et al: Exploring the phenotypic consequences of

- tissue specific gene expression variation inferred from GWAS summary statistics. Nat
 Commun 2018, 9:1825.
- Barbeira AN, Pividori M, Zheng J, Wheeler HE, Nicolae DL, Im HK: Integrating
 predicted transcriptome from multiple tissues improves association detection. *PLoS Genet* 2019, 15:e1007889.
- Ma X, Wang P, Xu G, Yu F, Ma Y: Integrative genomics analysis of various omics data
 and networks identify risk genes and variants vulnerable to childhood-onset asthma. *BMC Med Genomics* 2020, 13:123.
- 42. Xu M, Li J, Xiao Z, Lou J, Pan X, Ma Y: Integrative genomics analysis identifies
 promising SNPs and genes implicated in tuberculosis risk based on multiple omics
 datasets. Aging (Albany NY) 2020, 12:19173-19220.
- von Mering C, Huynen M, Jaeggi D, Schmidt S, Bork P, Snel B: STRING: a database of
 predicted functional associations between proteins. *Nucleic Acids Res* 2003, 31:258-261.
- Szklarczyk D, Santos A, von Mering C, Jensen LJ, Bork P, Kuhn M: STITCH 5:
 augmenting protein-chemical interaction networks with tissue and affinity data. *Nucleic Acids Res* 2016, 44:D380-384.
- 45. Calderon D, Bhaskar A, Knowles DA, Golan D, Raj T, Fu AQ, Pritchard JK: Inferring
 Relevant Cell Types for Complex Traits by Using Single-Cell Gene Expression. Am J
 Hum Genet 2017, 101:686-699.
- 46. Chang CC, Chow CC, Tellier LC, Vattikuti S, Purcell SM, Lee JJ: Second-generation
 PLINK: rising to the challenge of larger and richer datasets. *Gigascience* 2015, 4:7.
- Jin S, Guerrero-Juarez CF, Zhang L, Chang I, Ramos R, Kuan CH, Myung P, Plikus MV,
 Nie Q: Inference and analysis of cell-cell communication using CellChat. *Nat Commun*2021, 12:1088.
- Ghoussaini M, Mountjoy E, Carmona M, Peat G, Schmidt EM, Hercules A, Fumis L,
 Miranda A, Carvalho-Silva D, Buniello A, et al: Open Targets Genetics: systematic
 identification of trait-associated genes using large-scale genetics and functional
 genomics. Nucleic Acids Res 2021, 49:D1311-d1320.
- 49. Battle A, Brown CD, Engelhardt BE, Montgomery SB: Genetic effects on gene expression
 across human tissues. *Nature* 2017, 550:204-213.
- Wang Q, Chen R, Cheng F, Wei Q, Ji Y, Yang H, Zhong X, Tao R, Wen Z, Sutcliffe JS, et
 al: A Bayesian framework that integrates multi-omics data and gene networks predicts
 risk genes from schizophrenia GWAS data. Nat Neurosci 2019, 22:691-699.
- Ma Y, Li MD: Establishment of a Strong Link Between Smoking and Cancer
 Pathogenesis through DNA Methylation Analysis. Sci Rep 2017, 7:1811.
- 52. Auwul MR, Rahman MR, Gov E, Shahjaman M, Moni MA: Bioinformatics and machine
 learning approach identifies potential drug targets and pathways in COVID-19. Brief
 Bioinform 2021.
- More SA, Patil AS, Sakle NS, Mokale SN: Network analysis and molecular mapping for
 SARS-CoV-2 to reveal drug targets and repurposing of clinically developed drugs.
 Virology 2021, 555:10-18.
- Manne BK, Denorme F, Middleton EA, Portier I, Rowley JW, Stubben C, Petrey AC, Tolley
 ND, Guo L, Cody M, et al: Platelet gene expression and function in patients with
 COVID-19. *Blood* 2020, 136:1317-1329.
- 55. Shaath H, Vishnubalaji R, Elkord E, Alajez NM: Single-Cell Transcriptome Analysis
 Highlights a Role for Neutrophils and Inflammatory Macrophages in the Pathogenesis
 of Severe COVID-19. Cells 2020, 9.
- 56. Rydyznski Moderbacher C, Ramirez SI, Dan JM, Grifoni A, Hastie KM, Weiskopf D,
 Belanger S, Abbott RK, Kim C, Choi J, et al: Antigen-Specific Adaptive Immunity to

985		SARS-CoV-2 in Acute COVID-19 and Associations with Age and Disease Severity.
986		<i>Cell</i> 2020, 183: 996-1012.e1019.
987	57.	King KR, Aguirre AD, Ye YX, Sun Y, Roh JD, Ng RP, Jr., Kohler RH, Arlauckas SP,
988		Iwamoto Y, Savol A, et al: IRF3 and type I interferons fuel a fatal response to
989		myocardial infarction. Nat Med 2017, 23:1481-1487.
990	58.	Hadjadj J, Yatim N, Barnabei L, Corneau A, Boussier J, Smith N, P ér éH, Charbit B, Bondet
991		V, Chenevier-Gobeaux C, et al: Impaired type I interferon activity and inflammatory
992		responses in severe COVID-19 patients. Science 2020, 369:718-724.
993	59.	Lippi G, Plebani M, Henry BM: Thrombocytopenia is associated with severe
994		coronavirus disease 2019 (COVID-19) infections: A meta-analysis. Clin Chim Acta 2020,
995		506: 145-148.
996	60.	Ma C, Cheung AF, Chodon T, Koya RC, Wu Z, Ng C, Avramis E, Cochran AJ, Witte ON,
997		Baltimore D, et al: Multifunctional T-cell analyses to study response and progression
998		in adoptive cell transfer immunotherapy. Cancer Discov 2013, 3:418-429.
999	61.	Akondy RS, Fitch M, Edupuganti S, Yang S, Kissick HT, Li KW, Youngblood BA,
1000		Abdelsamed HA, McGuire DJ, Cohen KW, et al: Origin and differentiation of human
1001		memory CD8 T cells after vaccination. Nature 2017, 552:362-367.
1002	62.	Andrade F, Fellows E, Jenne DE, Rosen A, Young CS: Granzyme H destroys the function
1003		of critical adenoviral proteins required for viral DNA replication and granzyme B
1004		inhibition. <i>Embo</i> i 2007. 26: 2148-2157.
1005	63.	Li Y, Hou G, Zhou H, Wang Y, Tun HM, Zhu A, Zhao J, Xiao F, Lin S, Liu D, et al: Multi-
1006		platform omics analysis reveals molecular signature for COVID-19 pathogenesis.
1007		prognosis and drug target discovery. Signal Transduct Target Ther 2021, 6:155.
1008	64.	Bruchez A. Sha K. Johnson J. Chen L. Stefani C. McConnell H. Gaucherand L. Prins R.
1009		Matrevek KA. Hume AJ. et al: MHC class II transactivator CIITA induces cell
1010		resistance to Ebola virus and SARS-like coronaviruses. Science 2020, 370:241-247.
1011	65.	Wein AN, McMaster SR, Takamura S, Dunbar PR, Cartwright EK, Hayward SL, McManus
1012		DT. Shimaoka T. Ueha S. Tsukui T. et al: CXCR6 regulates localization of tissue-resident
1013		memory CD8 T cells to the airways. J Exp Med 2019. 216:2748-2762.
1014	66.	Takamura S, Kato S, Motozono C, Shimaoka T, Ueha S, Matsuo K, Mivauchi K, Masumoto
1015		T. Katsushima A. Nakayama T. et al: Interstitial-resident memory CD8(+) T cells sustain
1016		frontline epithelial memory in the lung. J Exp Med 2019, 216 :2736-2747.
1017	67.	Zhao J. Yang Y. Huang H. Li D. Gu D. Lu X. Zhang Z. Liu L. Liu T. Liu Y. et al:
1018		Relationship between the ABO Blood Group and the COVID-19 Susceptibility. Clin
1019		Infect Dis 2020.
1020	68.	Klok FA, Kruip M, van der Meer NJM, Arbous MS, Gommers D, Kant KM, Kaptein FHJ,
1021		van Paassen J. Stals MAM. Huisman MV. Endeman H: Incidence of thrombotic
1022		complications in critically ill ICU patients with COVID-19. Thromb Res 2020. 191:145-
1023		147.
1024	69.	Grillet F. Behr J. Calame P. Aubry S. Delabrousse E: Acute Pulmonary Embolism
1025		Associated with COVID-19 Pneumonia Detected with Pulmonary CT Angiography.
1026		Radiology 2020. 296:E186-e188
1027	70	Poran A. Harianto D. Mallov M. Arieta CM. Rothenberg DA. Lenkala D. van Buuren MM
1028		Addona TA, Rooney MS, Srinivasan L, Gavnor RB: Sequence-based prediction of SARS-
1020		CoV-2 vaccine targets using a mass snectrometry-based bioinformatics predictor
1020		identifies immunogenic T cell enitones. Genome Med 2020 12:70
1031	71	Soudia SM Ruiz AL. Marie IC Lauvan G' Inflammatory monocytes activate memory
1032	/ 1 •	CD8(+) T and innate NK lymphocytes independent of cognate antigen during
1033		microbial nathogen invasion. Immunity 2012, 37:549-562
1055		mer ostar partogen myastan mananty 2012, 0160 17 502.

- 72. Ziegler-Heitbrock L: The CD14+ CD16+ blood monocytes: their role in infection and 1034 inflammation. J Leukoc Biol 2007, 81:584-592. 1035 Kawanaka N, Yamamura M, Aita T, Morita Y, Okamoto A, Kawashima M, Iwahashi M, 73. 1036 Ueno A, Ohmoto Y, Makino H: CD14+, CD16+ blood monocytes and joint inflammation 1037 in rheumatoid arthritis. Arthritis Rheum 2002, 46:2578-2586. 1038 Hambleton S, Goodbourn S, Young DF, Dickinson P, Mohamad SM, Valappil M, 74. 1039 McGovern N, Cant AJ, Hackett SJ, Ghazal P, et al: STAT2 deficiency and susceptibility 1040 to viral illness in humans. Proc Natl Acad Sci U S A 2013, 110:3053-3058. 1041 75. Samji T, Khanna KM: Understanding memory CD8(+) T cells. Immunol Lett 2017, 1042 **185:**32-39. 1043 Nie Z. Hu G. Wei G. Cui K. Yamane A. Resch W. Wang R. Green DR. Tessarollo L. 1044 76. Casellas R, et al: c-Myc is a universal amplifier of expressed genes in lymphocytes and 1045 embryonic stem cells. Cell 2012, 151:68-79. 1046 1047 77. Jouan Y, Guillon A, Gonzalez L, Perez Y, Boisseau C, Ehrmann S, Ferreira M, Daix T, Jeannet R, Francois B, et al: Phenotypical and functional alteration of unconventional 1048 T cells in severe COVID-19 patients. J Exp Med 2020, 217. 1049 78. Finucane HK, Reshef YA, Anttila V, Slowikowski K, Gusev A, Byrnes A, Gazal S, Loh 1050
- PR, Lareau C, Shoresh N, et al: Heritability enrichment of specifically expressed genes
 identifies disease-relevant tissues and cell types. *Nat Genet* 2018, 50:621-629.

1053 1054



COVID-19 severity

S100A8, S100A9,

S100A12, IFITM1

Inflammatory and cytokine genes

megakaryocytes

Epithelial cells

Elevated cell-to-cell interactions enhance the resident to lung airway

Figure 1





Figure 3





